- New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress
- Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress (WVC) in Washington, DC, April 18 - 21, 2022. In addition, the latest data on its protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be presented at both WVC and the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in in Lisbon, Portugal, April 23 - 26, 2022. Data from eight abstracts and presentations, including four oral presentations, will be presented across the two congresses.
Gregory M. Glenn, M.D., President, Research and Development, Novavax, said: "Our presence at these two leading industry conferences shows our ongoing commitment to addressing COVID-19, and the advances we have made towards a next-generation influenza vaccine. We look forward to sharing these updates that further demonstrate the potential for our platform."
Key Novavax presentations during WVC:
| Glenn, G | How long will our immunity against COVID-19 last for and will our vaccines continue to work against VoCs? | PanelApril 19, 20228:45 - 9:45 ET |
| Kim, D | Monitoring COVID-19 Vaccine Safety under Emergency Use Authorization: Challenges and Lessons? | PanelApril 20, 202212:10 - 1:10 ET |
| Glenn, G | Clinical Update on Novavax's Recombinant Nanoparticle Protein Subunit COVID-19 Vaccine as a Booster | OralSession COVID & Beyond - M4April 20, 202212:40 - 12:00 ET |
| Shinde, V | Update on Novavax' NanoFlu* vaccine and COVID-19-Influenza Combination Vaccine development | OralSession Influenza and Respiratory - M4April 20, 202212:40 - 1:10 ET |
*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.
Key Novavax presentations during ECCMID:
| Toback, S | Ongoing safety and efficacy of the NVX-CoV2373 COVID-19 vaccine in the United Kingdom | Abstract #04525OralSession Late breaking updates on COVID vaccinationApril 25, 202216:15 - 17:15 CET |
| Shinde, V | Long-term durability of antigen-specific polyfunctional CD4+ T cell responses against vaccine-homologous and antigenically drifted viruses: results of a phase III trial of a recombinant quadrivalent hemagglutinin saponin-adjuvanted nanoparticle influenza | Abstract #1197OralSession Viral respiratory infections: Influenza and RSVApril 26, 202211:00 - 12:00 CET |
| ??ez, G | Safety, efficacy and effectiveness of a SARS-CoV-2 adjuvanted recombinant spike protein vaccine (NVX-CoV2373) in a phase III trial in adolescents (PREVENT-19) | Abstract #04455PosterSession 12g. Vaccine development, trials, efficacy, policyApril 25, 202212:00 - 13:00 CET |
| ??ez, G | Molecular epidemiology of SARS-CoV-2 strains identified during a phase III, efficacy and safety trial of NVX-CoV2373 vaccine (PREVENT-19) in the United States and Mexico | Abstract #00284PosterSession 12l. Virus evolution, variants, and impactApril 25, 202212:00 - 13:00 CET |
| Beyhaghi, H | Reported pregnancies and associated outcomes across the NVX-CoV2373 COVID-19 vaccine clinical development programme | Abstract #01705PosterSession 12g. Vaccine development, trials, efficacy, policyApril 25, 202212:00 - 13:00 CET |
| Marchese, A | COVID-19 vaccine receptivity and preferences among "vaccine hesitants" | Abstract #04362PosterSession 12g. Vaccine development, trials, efficacy, policyApril 25, 202212:00 - 13:00 CET |
For more information or to register, visit the World Vaccine Congress Washington 2022 and the 32nd European Congress of Clinical Microbiology & Infectious Diseases websites.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and its quadrivalent influenza investigational vaccine candidate, previously referred to as NanoFlu. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on LinkedIn,.
Contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com
Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg